Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use

BMC Medical Genomics

Volumn 7, Issue 1, 2014, Pages

  Van Laar, Ryan ^a   Flinchum, Rachel ^a   Brown, Nathan ^a   Ramsey, Joseph ^a   Riccitelli, Sam ^a   Heuck, Christoph ^b   Barlogie, Bart ^b   Shaughnessy Jr , John D ^a  

^a Signal Genetics LLC   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RNA; SYNDECAN 1;

ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; MYELOMA PROGNOSTIC RISK SCORE; OVERALL SURVIVAL; PLASMA CELL; PRIORITY JOURNAL; RECURRENCE RISK; REPRODUCIBILITY; SCORING SYSTEM; STANDARDIZATION; SURVIVAL TIME;

BIOPSY, NEEDLE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MULTIPLE MYELOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEER REVIEW, RESEARCH; PLASMA CELLS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RNA; SYNDECAN-1; TREATMENT OUTCOME;

EID: 84901465114     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-7-25     Document Type: Article

References (29)

1. Gene expression profiling predicts clinical outcome of breast cancer. Veer LJ, v 't Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH, Nature 2002 415 6871 530 536 10.1038/415530a 11823860 (Pubitemid 34130608)
2. An online gene expression assay for determining adjuvant therapy eligibility in patients with stage 2 or 3 colon cancer. Van Laar RK, Br J Cancer 2010 103 12 1852 1857 10.1038/sj.bjc.6605970 21119668
3. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, Radmacher M, Simon R, Yakhini Z, Ben-Dor A, Sampas N, Dougherty E, Wang E, Marincola F, Gooden C, Lueders J, Glatfelter A, Pollock P, Carpten J, Gillanders E, Leja D, Dietrich K, Beaudry C, Berens M, Alberts D, Sondak V, Nature 2000 406 6795 536 540 10.1038/35020115 10952317 (Pubitemid 30625740)
4. An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Roepman P, Jassem J, Smit EF, Muley T, Niklinski J, van de Velde T, Witteveen AT, Rzyman W, Floore A, Burgers S, Giaccone G, Meister M, Dienemann H, Skrzypski M, Kozlowski M, Mooi WJ, van Zandwijk N, Clin Cancer Res 2009 15 1 284 290 10.1158/1078-0432.CCR-08-1258 19118056
5. Molecular portraits of human breast tumours. Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C, Pollack J, Ross D, Johnsen H, Akslen L, Nature 2000 406 6797 747 752 10.1038/35021093 10963602
6. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Shaughnessy JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B, Blood 2007 109 6 2276 2284 10.1182/blood-2006-07-038430 17105813 (Pubitemid 46425864)
7. Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival. Nair B, Shaughnessy JD, Zhou Y, Astrid-Cartron M, Qu P, van Rhee F, Anaissie E, Alsayed Y, Waheed S, Hollmig K, Szymonifka J, Petty N, Hoering A, Barlogie B, Blood 2009 113 26 6572 6575 10.1182/blood-2009-02-207803 19389881
8. Using genomics to identify high-risk myeloma after autologous stem cell transplantation. Shaughnessy JD, Barlogie B, Biol Blood Marrow Transplant 2006 12 1 77 80 10.1016/j.bbmt.2005.10.002 16399589 (Pubitemid 43034124)
9. The molecular classification of multiple myeloma. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD, Blood 2006 108 6 2020 2028 10.1182/blood-2005-11-013458 16728703 (Pubitemid 44395016)
10. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics. Shaughnessy JD, Haessler J, Van Rhee F, Anaissie E, Pineda-Roman M, Cottler-Fox M, Hollmig K, Zangari M, Mohiuddin A, Alsayed Y, Grazziutti M, Epstein J, Crowley J, Barlogie B, Br J Haematol 2007 137 6 530 536 10.1111/j.1365-2141.2007.06586.x 17489983 (Pubitemid 46817333)
11. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Barlogie B, Anaissie E, Van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, Cottler-Fox M, Mohiuddin A, Alsayed Y, Tricot G, Bolejack V, Zangari M, Epstein J, Petty N, Steward D, Jenkins B, Gurley J, Sullivan E, Crowley J, Shaughnessy JD, Br J Haematol 2007 138 2 176 185 10.1111/j.1365-2141.2007.06639.x 17593024 (Pubitemid 46978271)
12. Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature. Chng WJ, Kuehl WM, Bergsagel PL, Fonseca R, Leukemia 2007 22 2 459 461 17805328 (Pubitemid 351250562)
13. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Haessler J, Shaughnessy JD, Zhan F, Crowley J, Epstein J, van Rhee F, Anaissie E, Pineda-Roman M, Zangari M, Hollmig K, Mohiuddin A, Alsayed Y, Hoering A, Tricot G, Barlogie B, Clin Cancer Res 2007 13 23 7073 7079 10.1158/1078-0432.CCR-07-0527 18056185 (Pubitemid 350276890)
14. High-risk myeloma: a gene expression-based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone. Zhan F, Barlogie B, Mulligan G, Shaughnessy JD, Bryant B, Blood 2008 111 2 968 969 10.1182/blood-2007-10-119321 18182586
15. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in Low-risk patients: a study of the intergroupe francophone du myélome. Decaux O, Lodé L, Magrangeas F, Charbonnel C, Gouraud W, Jézéquel P, Attal M, Harousseau J-L, Moreau P, Bataille R, Campion L, Avet-Loiseau H, Minvielle S, J Clin Oncol 2008 26 29 4798 4805 10.1200/JCO.2007.13.8545 18591550
16. Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile. Zhou Y, Nair B, Shaughnessy JD Jr, Cartron M-A, Haessler J, Anaissie E, Van Rhee F, Crowley J, Barlogie B, Br J Haematol 2009 145 5 637 641 10.1111/j.1365-2141.2009.07670.x 19344415
17. Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Dickens NJ, Walker BA, Leone PE, Johnson DC, Brito JL, Zeisig A, Jenner MW, Boyd KD, Gonzalez D, Gregory WM, Ross FM, Davies FE, Morgan GJ, Clin Cancer Res 2010 16 6 1856 1864 10.1158/1078-0432.CCR-09-2831 20215539
18. High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Zhou Y, Chen L, Barlogie B, Stephens O, Wu X, Williams DR, Cartron M-A, van Rhee F, Nair B, Waheed S, Pineda-Roman M, Alsayed Y, Anaissie E, Shaughnessy JD, Proc Natl Acad Sci 2010 107 17 7904 7909 10.1073/pnas.0908441107 20385818
19. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Hose D, Rème T, Hielscher T, Moreaux J, Messner T, Seckinger A, Benner A, Shaughnessy JD, Barlogie B, Zhou Y, Hillengass J, Bertsch U, Neben K, Möhler T, Rossi JF, Jauch A, Klein B, Goldschmidt H, Haematologica 2011 96 1 87 95 10.3324/haematol.2010.030296 20884712
20. Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. van Rhee F, Szymonifka J, Anaissie E, Nair B, Waheed S, Alsayed Y, Petty N, Shaughnessy JD, Hoering A, Crowley J, Barlogie B, Blood 2010 116 8 1220 1227 10.1182/blood-2010-01-264333 20501894
21. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, Bertsch U, Buijs A, Stevens-Kroef M, Beverloo HB, Vellenga E, Zweegman S, Kersten M-J, van der Holt B, el Jarari L, Mulligan G, Goldschmidt H, van Duin M, Sonneveld P, Blood 2010 116 14 2543 2553 10.1182/blood-2009-12- 261032 20574050
22. Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. Kumar SK, Uno H, Jacobus SJ, Wier SAV, Ahmann GJ, Henderson KJ, Callander NS, Haug JL, Siegel DS, Greipp PR, Fonseca R, Rajkumar SV, Blood 2011 118 16 4359 4362 10.1182/blood-2011-03-342089 21860025
23. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fassas A, Crowley J, Tricot G, Barlogie B, Shaughnessy J, Blood 2002 99 5 1745 1757 10.1182/blood.V99.5.1745 11861292 (Pubitemid 34533050)
24. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I. Passing H, Bablok, J Clin Chem Clin Biochem 1983 21 11 709 720 6655447 (Pubitemid 14208512)
25. R Development Core Team, R: A language and environment for statistical computing Vienna, Austria: R Foundation for Statistical Computing 2008 ISBN 3-900051-07-0, http://www.R-project.org
26. Bioconductor: open software development for computational biology and bioinformatics. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J, Genome Biol 2004 5 10 80 10.1186/gb-2004-5-10- r80 15461798
27. Converting a breast cancer microarray signature into a high-throughput diagnostic test. Glas AM, Floore A, Delahaye LJ, Witteveen AT, Pover RC, Bakx N, Lahti-Domenici JS, Bruinsma TJ, Warmoes MO, Bernards R, Wessels LF, Van't Veer LJ, BMC Genomics 2006 7 278 10.1186/1471-2164-7-278 17074082 (Pubitemid 44773844)
28. Prediction of cytogenetic abnormalities with gene expression profiles. Zhou Y, Zhang Q, Stephens O, Heuck CJ, Tian E, Sawyer JR, Cartron-Mizeracki M-A, Qu P, Keller J, Epstein J, Barlogie B, Shaughnessy JD, Blood 2012 119 21 148 e150 http://bloodjournal.hematologylibrary.org/content/119/21/e148 10.1182/blood-2011-10-388702 22496154
29. Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with Low expression of the glucocorticoid receptor gene NR3C1. Heuck CJ, Szymonifka J, Hansen E, Shaughnessy JD, Usmani SZ, van Rhee F, Anaissie E, Nair B, Waheed S, Alsayed Y, Petty N, Bailey C, Epstein J, Hoering A, Crowley J, Barlogie B, Clin Cancer Res 2012 18 19 5499 5506 10.1158/1078-0432.CCR-12-0019 22855579